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mIBACKGROUND Heart failure guidelines recommend up-titration of angiotensin-converting enzyme (ACE)
inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to
doses used in randomized clinical trials, but these recommended doses are often not reached. Up-titration may,
however, not be necessary in all patients.
OBJECTIVES This study sought to establish the role of blood biomarkers to determine which patients should or should
not be up-titrated.
METHODS Clinical outcomes of 2,516 patients with worsening heart failure from the BIOSTAT-CHF (BIOlogy Study to
Tailored Treatment in Chronic Heart Failure) were compared between 3 theoretical treatment scenarios: scenario A, in
which all patients are up-titrated to >50% of recommended doses; scenario B, in which patients are up-titrated
according to a biomarker-based treatment selection model; and scenario C, in which no patient is up-titrated to >50% of
recommended doses. The study conducted multivariable Cox regression using 161 biomarkers and their interaction with
treatment, weighted for treatment-indication bias to estimate the expected number of deaths or heart failure
hospitalizations at 24 months for all 3 scenarios.
RESULTS Estimated death or hospitalization rates in 1,802 patients with available (bio)markers were 16%, 16%, and
26%, respectively, in the ACE inhibitor/ARB up-titration scenarios A, B, and C. Similar rates for beta-blocker and MRA
up-titration scenarios A, B, and C were 23%, 19%, and 24%, and 12%, 11%, and 24%, respectively. If up-titration
was successful in all patients, an estimated 9.8, 1.3, and 12.3 events per 100 treated patients could be prevented at
24 months by ACE inhibitor/ARB, beta-blocker, and MRA therapy, respectively. Similar numbers were 9.9, 4.7, and 13.1 if
up-titration treatment decision was based on a biomarker-based treatment selection model.
CONCLUSIONS Up-titrating patients with heart failure based on biomarker values might have resulted in fewer deaths
or hospitalizations compared with a hypothetical scenario in which all patients were successfully up-titrated.
(J Am Coll Cardiol 2018;71:386–98) © 2018 by the American College of Cardiology Foundation.N 0735-1097/$36.00 https://doi.org/10.1016/j.jacc.2017.11.041
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ARB = angiotensin receptor
blocker
BNP = B-type natriuretic
peptide
BUN = blood urea nitrogen
CI = conﬁdence interval




NT-proBNP = N-terminal pro–
B-type natriuretic peptide
WAP-4C = WAP 4-disulﬁde
core domain protein HE4
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387M ajor improvements in pharmaceuticaland device heart failure treatment ofheart failure have been achieved in the
past year. Evidence from large randomized clinical
trials demonstrates that angiotensin-converting
enzyme (ACE) inhibitors, beta-blockers, and mineral-
ocorticoid receptor antagonists (MRAs) improve clin-
ical outcome in patients with mild-to-moderate
heart failure (1–8). In large randomized clinical trials,
treatment doses were up-titrated to pre-speciﬁed
doses, which have become the guideline-
recommended doses (9–12). Despite these improve-
ments and recommendations, the prognosis of
patients with heart failure remains poor (13–16), and
in daily clinical practice the majority of patients do
not achieve recommended doses (17–19). Although it
is expected that most patients that achieve recom-
mended doses will beneﬁt from treatment, selected
patients may not beneﬁt from the recommended
doses, but will experience side effects of ACE inhibi-
tors and beta-blocker treatment. A personalized med-
icine approach in which patients who will not beneﬁt
from recommended ACE inhibitor/ARB and beta-
blocker heart failure treatment might be selected by
biomarkers, and might reduce the number of patients
receiving treatment without beneﬁt and improve
overall outcome.SEE PAGE 399In this in silico study, we used data from the
BIOSTAT-CHF (BIOlogy Study to Tailored Treatment
in Chronic Heart Failure) project to identify such
treatment selection markers. We hypothesized that
biomarkers measured at baseline in serum or plasma
of heart failure patients can identify whether patients
beneﬁt from recommended heart failure treatment or
not. We developed models to estimate this beneﬁt
using 161 established and novel biomarkers, including
standard biochemical blood parameters. We
compared 3 theoretical treatment scenarios: scenarioThis work was supported by a grant from the European Commission (FP
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>50% of recommended doses according to
the European Society of Cardiology guide-
lines (9–11); scenario B, in which patients are
up-titrated by a biomarker-based treatment
selection model; and scenario C, in which no
patient is treated at >50% of recommended
dose.
METHODS
PATIENTS. BIOSTAT-CHF is a multicenter
prospective study of 2,516 patients from 69
centers in 11 European countries (20).
Included patients were >18 years of age with
symptoms of new onset or worsening heart
failure, conﬁrmed either by a left ventricular
ejection fraction (LVEF) of #40% or B-type
natriuretic peptide (BNP) or N-terminal pro–B-type
natriuretic peptide (NT-proBNP) plasma levels >400
pg/ml or >2,000 pg/ml, respectively. At inclusion,
patients were treated with either oral or intravenous
furosemide $40 mg/day or equivalent at the time of
inclusion, and were not previously treated with
evidence-based therapies (ACE inhibitor/ARB and
beta-blocker) or were receiving #50% of the target
doses of these drugs at the time of inclusion and
had an anticipated initiation or up-titration of ACE
inhibitor/ARB or beta-blocker therapy by the treating
physician. Institutional Review Board approval was
obtained in all countries.
EVIDENCE-BASED HEART FAILURE TREATMENT.
Patients were treated according to evidence based
European Society of Cardiology heart failure guide-
lines available at time of inclusion (9–11). These
recommend up-titrating patients to recommended
doses of ACE inhibitors/ARBs and beta-blockers, un-
less not tolerated or contraindicated (9–11). In
BIOSTAT-CHF, suboptimally treated patients were
included, and physicians were encouraged to7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29).
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388up-titrate patients to recommended treatment doses
within 3 months after inclusion.
We recently published data from BIOSTAT-CHF
showing that up-titrating patients to at least 50% of
recommended ACE inhibitor/ARB and beta-blocker
doses results in comparable survival or heart–
failure-related hospitalization reduction compared
with patients that reached $100% of recommended
doses (21). We therefore considered patients success-
fully up-titrated when >50% of recommended dose
was achieved after 3 months of up-titration. Inversely,
we deﬁned nonresponders as patients who did not
achieve more that 50% recommended treatment dose.
All analyses were separately performed for ACE
inhibitors/ARBs and beta-blockers. In addition to ACE
inhibitor/ARB and beta-blocker treatment, we also
looked at MRA guideline-recommended treatment.
Here we deﬁned successful treatment as patients who
achieved $50% of recommended treatment, and non-
responding patient when <50% of recommended
treatment dose was achieved. MRA treatment data
was available at 9 months after inclusion.
DISEASE OUTCOME. Median follow-up of the
BIOSTAT-CHF project was 21 months with an inter-
quartile range of 15 to 27 months. Primary patient
outcome in BIOSTAT-CHF was the ﬁrst occurrence of
all-cause mortality or heart failure–related hospitali-
zation. Survival time was calculated from date of in-
clusion in BIOSTAT-CHF to date of death or heart
failure hospitalization or date of censoring. Only pa-
tients who were at least followed for 3 months were
included in the present analysis.
BIOMARKERS. A total of 161 biomarkers were
considered as treatment selection markers. All
markers were measured at inclusion of the patients.
This included standard biochemical blood-
parameters (hemoglobin, hematocrit, sodium, total
cholesterol, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, glucose, serum
creatinine, blood urea nitrogen [BUN], bilirubin,
serum iron, potassium), heart failure markers (LVEF,
NT-proBNP, and BNP), 29 markers from the Luminex
multiplexed bead-based immunoassay (Alere, San
Diego, California) heart failure panel (22,23), and 92
peptide markers from a high-throughput technique
using the Olink Proseek Multiplex Cardiovascular
(CVD) III96x96 kit (Olink Proteomics, Uppsala,
Sweden), which measures 92 selected inﬂammation-
related proteins simultaneously in 1-ml plasma
samples. The kit uses a proximity extension assay
technology in which 92 oligonucleotide-labeled
antibody probe pairs are allowed to bind to their
respective target present in the sample.The 92 peptides measured by Olink were normal-
ized in arbitrary normalized protein expression units.
Other biomarkers were normalized using Box-Cox
transformations when deemed necessary. A com-
plete list of all biomarkers and their summary statis-
tics are shown in Online Table 1.
STATISTICAL ANALYSIS. Imputat ion of miss ing
data . Patients in whom >50% or more biomarker
values weremissing were not included in the analyses.
Remainingmissing valueswere imputed using random
forests regression models implemented in the mice
package (24) of the R statistical program version 3.2.4
(R Project for Statistical Computing, Vienna, Austria).
Five completed datasets were created.
Ind icat ion b ias . Because BIOSTAT-CHF is not a
randomized study, we adjusted for treatment indi-
cation bias. All analyses of the effect of successful up-
titration treatment on mortality or hospitalization
risk were inversely weighted with the probability of
the given treatment. Given that treatment is deﬁned
here as a successful up-titration to >50% of European
Society of Cardiology–recommended doses for ACE
inhibitor/ARB or beta-blocker or not or $50% Euro-
pean Society of Cardiology–recommended MRA
treatment dose. The probability of given treatment
for a speciﬁc patient was modeled using a logistic
regression model. All biomarkers were considered as
predictor variables for successful up-titration. In
addition, we considered 39 demographic and clinical
predictor variables for prediction of the successful
outcome of the up-titration (age, sex, race, body mass
index, blood pressure, heart rate, smoking, alcohol
use, heart failure etiology, heart failure duration,
New York Heart Association functional class, and
several heart failure symptoms and comorbid condi-
tions). We used lasso penalization to obtain sparse
logistic models consisting of a limited number of
predictor variables. Optimal penalty parameters were
obtained by 10-fold cross-validation. Analyses were
performed for each imputed dataset and the calcu-
lated treatment probabilities were averaged per pa-
tient over the 5 imputed datasets. Performance of the
logistic models was quantiﬁed using optimism-
corrected C-statistics using 100 bootstrap samples,
averaged over the imputed datasets.
Death or heart fa i lure hosp i ta l i zat ion and
treatment-b iomarker interact ion . Mortality or
heart failure hospitalization risk was modeled using
the Cox regression model with given treatment as a
stratum variable. Therefore, we did not assume pro-
portional hazards for the effect of treatment on
mortality or hospitalization risk. The assumed pro-
portional hazards assumption of the biomarkers was
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389checked using Grambsch and Therneau’s test imple-
mented in the cox.zph function of the R statistical
program (25).
We performed multivariable Cox regression with all
161 biomarkers. We used the split sample technique to
obtain a training sample consisting of 80% of the pa-
tients in the original index cohort and the remaining
20% of the patients formed the test sample. The split-
sample procedure was repeated 100 times. In all 100
training samples, we used lasso penalization to obtain
sparse Cox regression models consisting of a limited
number of the 161 biomarkers. Optimal penalty pa-
rameters were obtained by 10-fold cross-validation.
We performed separate analyses for patients who
were successfully up-titrated to >50% of recom-
mended treatment dose for either ACE inhibitors/
ARBs or beta-blockers and for patients who were
nonresponders as deﬁned by lack of up-titration
(#50% of recommended treatment dose). This
resulted in 6 different models predicting mortality or
heart failure hospitalization; 3 models predicting
mortality or heart failure hospitalization in success-
fully up-titrated patients for ACE inhibitors/ARBs,
beta-blockers, and MRAs, and 3 for nonresponding
patients who were up-titrated to #50% of recom-
mended ACE inhibitor/ARB and beta-blocker doses
and <50% recommended MRA dose. We stratiﬁed on
given treatment and considered both the main effects
of all biomarkers as well as all interactions of bio-
markers with treatment. In the 100 test samples, we
subsequently evaluated the goodness of ﬁt of the
selected sparse Cox regression models. We calculated
both calibration and discrimination statistics (C-sta-
tistic and shrinkage statistic). Moreover, the beneﬁt
of successful and not successful up-titration was
calculated for the patients in the test samples. All
analyses were inversely weighted with the probability
of the given treatment to account for indication bias.
Treatment beneﬁ t stat i s t i cs . We calculated the
expected number of events at 24 months follow-up
for 3 scenarios: scenario A, if all patients are suc-
cessfully up-titrated to >50% of recommended doses
according to the European Society of Cardiology
guidelines ($50% for MRAs); scenario B, if all patients
are up-titrated following a treatment strategy based
on the biomarker values; and scenario C, if no patient
is treated at >50% of recommended doses according
to the European Society of Cardiology heart failure
guidelines ($50% for MRAs). We performed all
analyses for ACE inhibitors/ARBs and beta-blockers
separately. For scenario B, we decided to up-titrate
when the probability of survival for mortality or
hospitalization at 24 months for up-titrating was
higher than for not up-titrating, and vice versa.The survival probabilities were based on the dif-
ference of a patient’s mean death or heart failure
hospitalization probability at 24 months follow-up
(S(t ¼ 24j...)) under both treatments according to the
sparse Cox regression models estimated for the
associated training sample:
Sðt ¼ 24jsuccessful up-titration;X ¼ xÞ
Sðt ¼ 24junsuccessful up-titration;X ¼ xÞ
where X¼x represents speciﬁc levels of the bio-
markers selected in the Cox models for predicting
mortality or heart failure hospitalization in the suc-
cessfully and not successfully up-titrated patients,
respectively. The difference was averaged over all
test samples that included the speciﬁc patient, and
was subsequently multiplied with total number of
patients. This beneﬁt statistic can be interpreted as
the number of deaths or heart failure hospitalizations
that is prevented at 24 months by successful up-
titrating to >50% of recommended doses according
to the European Society of Cardiology guidelines.
Beneﬁt statistics were calculated for each test
sample separately. The standard deviation of the
beneﬁt statistics over the 100 test samples was then
used as an estimate of the standard error of the mean
beneﬁt statistic.
RESULTS
Of the 2,516 patients included in the index cohort, 151
patients died, 23 patients were censored before
3 months follow-up, and 242 patients had an LVEF
>40%; these patients were excluded from the current
data analysis. Of the remaining 2,100 patients, there
were 298 patients with missing values on more than
50% of the biomarkers. Subsequent analyses were
done with data from the remaining 1,802 patients.
Because BIOSTAT-CHF is not a randomized trial, we
corrected for the probability of being up-titrated to
>50% of recommended treatment dose. Biomarkers
predictive for up-titration and subsequent indication
bias correction are presented in the Online Appendix.
Of the 1,802 patients, 529 (29%) were up-titrated to
>50% of recommended ACE inhibitor/ARB dose and
318 (18%) were up-titrated to >50% of recommended
beta-blocker dose. We have MRA treatment data for
1,423 patients at 9 months after inclusion. Of these
1,423 patients, 14% (n ¼ 195) were successfully up-
titrated to $50% recommended treatment dose (2%
[n ¼ 28] to >50% recommended doses). Patient
characteristics of patients achieving >50% recom-
mended ACE inhibitor/ARB and beta-blocker dose
and $50% recommended MRA dose and of those
who did not respond to recommended treatment are
presented in Table 1.
TABLE 1 Baseline Characteristics of the Patients Who Were Up-Titrated to >50% of Recommended ACE Inhibitor/ARB and Beta-Blocker and
$50% MRA Dose and Those Who Were Not






















100  28 29  18 61  39 48  38 54  38 52  39
% of recommended
beta-blocker dose
45  32 34  30 93  18 25  17 38  30 37  31
Age, yrs 66.36  11.85 68.15  12.12 0.004 66.14  12.63 67.94  11.92 0.02 63.21  12.35 67.71  11.89 <0.00001
Male 395 (75) 967 (76) 0.56 235 (74) 1,127 (76) 0.44 161 (83) 914 (74) 0.01
Caucasian 523 (99) 1,259 (99) 0.29 314 (99) 1,468 (99) 0.04 187 (96) 1,219 (99) 0.0006
BMI, kg/m2 28.93  6.02 27.49  5.26 <0.00001 28.41  5.57 27.81  5.51 0.09 28.84  5.55 27.87  5.51 0.02
Systolic blood pressure,
mm Hg
130.04  22.37 121.24  20.50 <0.00001 125.47  21.70 123.46  21.37 0.13 121.62  18.39 125.68  21.24 0.006
Diastolic blood pressure,
mm Hg
79.03  13.71 73.68  12.60 <0.00001 78.35  14.45 74.58  12.77 0.00002 75.03  11.24 76.36  13.35 0.14
Heart rate, beats/min 79.88  20.33 79.97  19.19 0.93 85.30  22.25 78.80  18.70 <0.00001 80.66  18.97 79.87  20.29 0.59
Smoking (current/ever/
never)
197/256/76 450/630/193 0.73 101/177/40 546/709/229 0.04 63/94/38 450/602/176 0.14
Alcohol use 368 (70) 909 (71) 0.45 203 (64) 1,074 (72) 0.003 132 (68) 872 (71) 0.33
Ischemic HF etiology 261 (49) 563 (44) 0.05 163 (51) 661 (45) 0.03 100 (51) 584 (48) 0.33















244 (46) 509 (40) 0.02 134 (42) 619 (42) 0.89 83 (43) 566 (46) 0.36














Edema 228 (43) 603 (47) 0.10 156 (49) 675 (45) 0.25 86 (44) 526 (43) 0.74
Orthopnea 150 (28) 431 (34) 0.02 82 (26) 499 (34) 0.006 62 (32) 366 (30) 0.58
Rales >1/3 up
lung ﬁelds
44 (19) 125 (19) 0.98 17 (12) 152 (20) 0.03 12 (13) 104 (18) 0.21
Jugular venous
pressure
111 (29) 281 (31) 0.45 63 (28) 329 (31) 0.37 43 (30) 240 (27) 0.43
Hepatomegaly 60 (11) 184 (14) 0.07 39 (12) 205 (14) 0.45 39 (20) 125 (10) 0.00007
Hypertension 349 (66) 731 (57) 0.0007 195 (61) 885 (60) 0.58 107 (55) 750 (61) 0.10
Atrial ﬁbrillation 209 (40) 564 (44) 0.06 163 (51) 610 (41) 0.0009 80 (41) 518 (42) 0.76
Myocardial infarction 188 (36) 491 (39) 0.23 113 (36) 566 (38) 0.38 61 (31) 441 (36) 0.21
PCI 106 (20) 285 (22) 0.27 72 (23) 319 (21) 0.65 39 (20) 260 (21) 0.71
CABG 70 (13) 220 (17) 0.03 47 (15) 243 (16) 0.48 23 (12) 183 (15) 0.25
None 427 (24) 932 (52) 0.02 234 (13) 1,125 (62) 0.52 136 (10) 969 (68) 0.004
Pacemaker only 28 (2) 89 (5) 16 (1) 101 (6) 8 (1) 80 (6)
ICD only 31 (2) 121 (7) 30 (2) 122 (7) 25 (2) 84 (6)
CRT only 11 (1) 24 (1) 7 (0) 28 (2) 5 (0) 19 (1)
ICD and CRT 31 (2) 102 (6) 30 (2) 103 (6) 20 (1) 72 (5)
Other 1 (0) 5 (0) 1 (0) 5 (0) 1 (0) 4 (0)
Diabetes mellitus 182 (34) 389 (31) 0.11 97 (31) 474 (32) 0.62 63 (32) 351 (29) 0.29
COPD 70 (13) 220 (17) 0.03 42 (13) 248 (17) 0.12 28 (14) 185 (15) 0.80
Stroke 40 (8) 122 (10) 0.17 20 (6) 142 (10) 0.06 12 (6) 112 (9) 0.17
Peripheral artery disease 46 (9) 142 (11) 0.12 27 (8) 161 (11) 0.21 16 (8) 121 (10) 0.47
Aldosterone
antagonists
267 (50) 719 (56) 0.02 150 (47) 836 (56) 0.003 156 (80) 621 (51) <0.00001
Loop diuretics 526 (99) 1,268 (100) 0.61 317 (100) 1,477 (100) 0.7 194 (99) 1,221 (99) 0.92
Digoxin 82 (16) 242 (19) 0.08 54 (17) 270 (18) 0.61 50 (26) 206 (17) 0.003
Hemoglobin, g/dl 12.69  1.73 12.00  2.00 <0.00001 12.52  1.81 12.00  2.00 0.13 12.71  1.79 13.00  2.00 0.14
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TABLE 1 Continued


















(n ¼ 1,228) p Value
eGFR MDRD formula,
ml/min/1.73 m2
71  22 64  24 <0.00001 68  24 65  23 0.09 73  20 67  23 0.001
Sodium, mmol/l 138.85  3.55 138.06  3.81 0.00004 138.62  3.46 138.22  3.81 0.07 138.56  3.84 138.53  3.60 0.91














Values are n, mean  SD, n (%), or median (interquartile range).
ACE¼ angiotensin-converting enzyme; ARB¼ angiotensin receptor blocker; BMI¼ body mass index; BNP¼ B-type natriuretic peptide; BUN¼ blood urea nitrogen; CABG¼ coronary artery bypass grafting;
COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; ICD ¼ implantable cardioverter-deﬁbrillator
LVEF ¼ left ventricular ejection fraction; MDRD ¼ Modiﬁcation of Diet in Renal Disease; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro B-type natriuretic peptide;
NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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391MULTIVARIABLE TREATMENT SELECTION MARKERS. To
distinguish patients who beneﬁted from up-titration
from those who did not, we created 2 models.
From 161 biomarkers, we ﬁrst identiﬁed the strongest
biomarkers to predict clinical events (death of heart
failure hospitalization) despite successful up-titration
with either ACE inhibitors/ARBs or beta-blockers.
Most frequently selected biomarkers are reported in
Online Table 2. BUN, ﬁbroblast growth factor 23, and
pro-enkephalin were the strongest predictors of
clinical events in patients that were successfully
up-titrated with ACE inhibitors/ARBs. Serum creati-
nine, galectin-3, ST2, and albumin were the strongest
predictors of clinical events in patients that
were successfully up-titrated with beta-blockers
(Online Table 3). Predictive biomarkers for events
in up-titrated patients with MRAs are presented in
Online Table 4.
In the second model, we identiﬁed the strongest
biomarkers to predict clinical events in patients who
were NOT successfully up-titrated with either ACE
inhibitors/ARBs or beta-blockers. Fibroblast growth
factor 23, BUN, cystatin C, ST2, WAP 4-disulﬁde core
domain protein HE4 (WAP-4C), and insulin-like
growth factor binding protein 2 were the strongest
predictors of clinical events in patients that were not
successfully up-titrated with ACE inhibitors/ARBs.
Fibroblast growth factor 23, cystatin C, BUN, WAP-4C,
and NT-proBNP were the strongest predictors of
clinical events in patients that were not successfully
up-titrated with beta-blockers.
The treatment selection models had reasonable
performances for the patients in the test sets. Aver-
aged C-statistics for ACE inhibitor/ARB models were
0.74 (95% conﬁdence interval [CI]: 0.68 to 0.80) in
up-titrated patients, and 0.77 (95% CI: 0.70 to 0.83) in
non–up-titrated patients, respectively. Beta-blockertreatment selection models averaged C-statistics
were 0.75 (95% CI: 0.70 to 0.82) in up-titrated pa-
tients, and 0.78 (95% CI: 0.73 to 0.83) in non–up-
titrated patients, respectively. C-statistics for MRA
treatment selection models were 0.65 (95% CI: 0.56 to
0.74) and 0.77 (95% CI: 0.71 to 0.86) in up-titrated and
non–up-titrated patients.
Using both models, we were able to calculate sur-
vival probability at 24 months for both scenarios
(successful or nonsuccessful up-titration). The sce-
nario with the highest probability was considered the
most beneﬁcial one for the individual patient. In 2%
(n ¼ 42) of patients, the highest probability was found
in patients who were not successfully up-titrated
with ACE inhibitors/ARBs. Characteristics of these
patients are presented in Table 2. Patients not
beneﬁtting from ACE inhibitor/ARB up-titration were
younger, more frequently smokers, with less atrial
ﬁbrillation and higher hemoglobin and BUN, but
lower heart rate and NT-proBNP levels. In 33%
(n ¼ 592) of patients, the highest survival probability
was found in patients who were not successfully up-
titrated with beta-blockers. Characteristics of these
patients are presented in Table 2. Patients not
beneﬁtting from beta-blocker up-titration were older,
leaner, and more frequently smokers or former
smokers. They also had less ischemic heart failure, but
more myocardial infarction, and other comorbidities.
They also had signiﬁcantly higher LVEF, NT-proBNP,
BUN, and creatinine levels, and lower diastolic blood
pressure, heart rate, hemoglobin, and estimated
glomerular ﬁltration rate levels. Up-titrating MRA
treatment was not beneﬁcial for 13% (n ¼ 184) of the
patients.
CLINICAL EVENTS ACCORDING TO THE 3
HYPOTHETICAL SCENARIOS. Kaplan-Meier curves
for ACE inhibitor/ARB scenarios are presented
TABLE 2 Characteristics of Patients Who Did Beneﬁt From ACE Inhibitor/ARB, Beta-Blocker, or MRA Up-Titration and Those Who Did Not


























37  31 41  32 37  31 36  32 37  32 37  28
Age, yrs 67.72  12.00 63.37  14.00 0.05 65.93  12.13 71.08  11.18 <0.00001 68.04  12.04 64.77  11.88 0.0001
Male 1,331 (76) 31 (74) 0.79 922 (76) 440 (74) 0.38 1,219 (77) 143 (62) <0.00001
Caucasian 1,742 (99) 40 (95) 0.08 1,194 (99) 588 (99) 0.54 1,555 (99) 227 (99) 0.42
BMI, kg/m2 27.89  5.55 28.82  4.22 0.18 28.37  5.72 26.99  4.98 <0.00001 27.86  5.55 28.27  5.39 0.30
Systolic blood pressure,
mm Hg
123.67  21.46 129.81  19.94 0.06 124.26  21.77 122.9  20.73 0.20 123.26  21.44 127.61  21.09 0.004
Diastolic blood pressure,
mm Hg
75.18  13.15 78.07  13.62 0.18 76.23  13.53 73.23  12.13 <0.00001 74.87  13.11 77.80  13.26 0.002
Heart rate,
beats/min
80.05  19.63 75.24  13.49 0.03 80.91  19.36 77.97  19.72 0.003 80.62  19.68 75.29  17.72 0.00004
Smoking (current/ever/
never)
626/866/268 21/20/1 0.03 417/584/209 230/302/60 0.0003 560/779/234 87/107/35 0.72
Alcohol use 1,246 (71) 31 (74) 0.68 857 (71) 420 (71) 0.94 1,094 (70) 183 (80) 0.0009
Ischemic HF etiology 801 (46) 23 (55) 0.23 582 (48) 242 (41) 0.004 715 (45) 109 (48) 0.54















731 (42) 22 (52) 0.16 498 (41) 255 (43) 0.44 618 (39) 135 (59) <0.00001














Edema 818 (46) 13 (31) 0.05 558 (46) 273 (46) 1.00 753 (48) 78 (34) 0.00009
Orthopnea 567 (32) 14 (33) 0.88 404 (33) 177 (30) 0.14 538 (34) 43 (19) <0.00001
Rales >1/3 up lung ﬁelds 166 (19) 3 (14) 0.58 108 (18) 61 (20) 0.43 159 (20) 10 (12) 0.10
Jugular venous pressure 387 (31) 5 (16) 0.07 256 (30) 136 (31) 0.80 365 (32) 27 (16) 0.00001
Hepatomegaly 240 (14) 4 (10) 0.44 166 (14) 78 (13) 0.75 224 (14) 20 (9) 0.02
Hypertension 1,052 (60) 28 (67) 0.37 713 (59) 367 (62) 0.21 940 (60) 140 (61) 0.69
Atrial ﬁbrillation 763 (43) 10 (24) 0.01 517 (43) 256 (43) 0.84 716 (46) 57 (25) <0.00001
Myocardial infarction 668 (38) 11 (26) 0.12 415 (34) 264 (45) 0.00002 595 (38) 84 (37) 0.74
PCI 385 (22) 6 (14) 0.24 248 (20) 143 (24) 0.08 345 (22) 46 (20) 0.53
CABG 282 (16) 8 (19) 0.60 180 (15) 110 (19) 0.04 254 (16) 36 (16) 0.87
None 1,326 (74) 33 (2) 0.31 927 (51) 432 (24) 0.39 1,177 (65) 182 (10) 0.37
Pacemaker only 116 (6) 1 (0) 70 (4) 47 (3) 105 (6) 12 (1)
ICD only 151 (8) 1 (0) 101 (6) 51 (3) 133 (7) 19 (1)
CRT only 34 (2) 1 (0) 25 (1) 10 (1) 34 (2) 1 (0)
ICD and CRT 127 (7) 6 (0) 83 (5) 50 (3) 118 (7) 15 (1)
Other 6 (0) 0 (0) 4 (0) 2 (0) 6 (0) 0 (0)
Diabetes mellitus 560 (32) 11 (26) 0.44 367 (30) 204 (34) 0.08 506 (32) 65 (28) 0.25
COPD 287 (16) 3 (7) 0.11 194 (16) 96 (16) 0.92 259 (16) 31 (14) 0.26
Stroke 162 (9) 0 (0) 0.04 101 (8) 61 (10) 0.17 148 (9) 14 (6) 0.1
Peripheral artery disease 185 (11) 3 (7) 0.48 120 (10) 68 (11) 0.31 173 (11) 15 (7) 0.04
Aldosterone antagonists 966 (55) 20 (48) 0.35 692 (57) 294 (50) 0.003 854 (54) 132 (58) 0.34
Loop diuretics 1,752 (100) 42 (100) 0.66 1,203 (99) 591 (100) 0.22 1,567 (100) 227 (99) 0.3
Digoxin 321 (18) 3 (7) 0.06 231 (19) 93 (16) 0.08 296 (19) 28 (12) 0.02
Hemoglobin, g/dl 12.36  1.85 13.00  1.00 0.004 12.79  1.73 12.00  2.00 <0.00001 12.40  1.87 12.23  1.68 0.17
















66.00  23.00 70.00  25.00 0.29 70.00  22.00 56.00  23.00 <0.00001 64.00  23.00 78.16  21.68 <0.00001
Sodium, mmol/l 138.28  3.75 138.95  3.88 0.27 138.42  3.64 138.03  3.97 0.04 138.11  3.84 139.58  2.79 <0.00001
Continued on the next page
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TABLE 2 Continued


















(n ¼ 229) p Value














Values are n, mean  SD, n (%), or median (interquartile range).
Abbreviations as in Table 1.




















Scenario A Scenario B Scenario C
Estimated Kaplan-Meier survival curves with the expected event-free survival rate and
time in months based on 3 scenarios (blue, orange, and gray lines): scenario A, if all
patients were up-titrated to >50% of recommended angiotensin-converting enzyme
(ACE) inhibitor/angiotensin receptor blocker (ARB) dose (blue); scenario B, if all patients
were up-titrated according to biomarker-selection model (orange); and scenario C, if
no patient was up-titrated to >50% of recommended ACE inhibitor/ARB dose (gray),
with 95% conﬁdence interval (dashed lines).
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393in Figure 1. Mortality or heart failure hospitalization
was highest in the scenario in which no patient was
up-titrated to $50% of the recommended dose. Pa-
tients who were up-titrated based on their biomarker
proﬁle had the lowest risk of death or heart failure
hospitalization.
Estimated event rate and averaged expected
events at 24 months for each of the 3 hypothetical
scenarios are presented in Table 3. If all patients were
successfully up-titrated to >50% of recommended
doses ACE inhibitors/ARBs (scenario A), estimated
death or hospital admission occurred in 297 (95% CI:
260 to 335) patients. If patients were up-titrated with
ACE inhibitors/ARBs following a treatment strategy
based on the biomarker values (scenario B), estimated
death or hospital admission occurred in 296 (95% CI:
260 to 333) patients. If no patient was treated with
>50% of recommended doses of ACE inhibitors/ARBs
(scenario C), estimated death or hospital admission
occurred in 474 (95% CI: 438 to 511) patients. Up-
titrating ACE inhibitors/ARBs to >50% of recom-
mended dose compared with #50% recommended
dose resulted in 174 fewer events (95% CI: 128 to 227;
p ¼ 0.0003). Per 100 treated patients, this means that
9.8 (95% CI: 7.1 to 12.6) fewer events were seen in this
scenario. The biomarkers-based approach led to 178
fewer events (95% CI: 130 to 226; p ¼ 0.0003)
compared with the #50% recommended dose group.
Per 100 treated patients this resulted in 9.9 (95% CI:
7.2 to 12.6) fewer events.
Kaplan-Meier curves for beta-blocker scenarios are
presented in Figure 2. Mortality or heart failure hos-
pitalization was highest in the scenario where no
patient was up-titrated to $50% of the recommended
dose. Patients who were up-titrated based on their
biomarker proﬁle had the lowest risk of death or heart
failure hospitalization, which was slightly lower
compared with a scenario in which all patients were
up-titrated to >50% of the recommended dose of ACE
inhibitors/ARBs.
Estimated event rate and averaged expected
events at 24 months for each of the 3 hypotheticalscenarios are presented in Table 3. If all patients were
successfully up-titrated to recommended beta-
blocker doses (scenario A), estimated death or hos-
pital admission occurred in 404 (95% CI: 332 to 477)
patients. If patients were up-titrated with beta-
blockers following a treatment strategy based on the
biomarker values (Scenario B), estimated death or
hospital admission occurred in 345 (95% CI: 300 to
389) patients. If no patient was treated with
TABLE 3 Estimation of Mortality or Heart Failure Hospitalizations at 24 Months
Scenario A Scenario B Scenario C
ACE inhibitor/ARB
Estimated event rate at 24 months 16 16 26
Estimated number of events 297 (260 to 335) 296 (260 to 333) 474 (438 to 511)
Estimated event reduction compared with scenario C 177 (128 to 227) 178 (130 to 226) —
Estimated event reduction compared with scenario C
per 100 treated patients
9.8 (7.1 to 12.6) 9.9 (7.2 to 12.6) —
Beta-blocker
Estimated event rate at 24 months 23 19 24
Estimated number of events 404 (332 to 477) 345 (300 to 389) 428 (391 to 466)
Estimated event reduction compared with scenario C 24 (–54 to 103) 84 (40 to 128) —
Estimated event reduction compared with scenario C
per 100 treated patients
1.3 (–3.0 to 5.7) 4.7 (2.2 to 7.1) —
MRA
Estimated event rate at 24 months 12 11 24
Estimated number of events 215 (150 to 280) 201 (147 to 255) 437 (405 to 469)
Estimated event reduction compared with scenario C 222 (147 to 298) 236 (170 to 303) —
Estimated event reduction compared with scenario C,
per 100 treated patients
12.3 (8.1 to 16.5) 13.1 (9.4 to 16.8) —
Values are % or n (95% conﬁdence interval). Scenario A was if all patients were successfully up-titrated to >50% of recommended dose, scenario B was if up-titration was based
on the biomarker treatment selection model, and scenario C was if no patient was successfully up-titrated for ACE inhibitors/ARBs.
Abbreviations as in Table 1.




















Scenario A Scenario B Scenario C
Estimated Kaplan-Meier survival curves with the expected event-free survival rate and
time in months based on 3 scenarios (blue, orange, and gray lines): scenario A, if all
patients were up-titrated to >50% of recommended beta-blocker dose (blue); scenario
B, if all patients were up-titrated according to biomarker-selection model (orange); and
scenario C, if no patient was up-titrated to >50% of recommended of beta-blocker
dose (gray), with 95% conﬁdence interval (dashed lines).
Ouwerkerk et al. J A C C V O L . 7 1 , N O . 4 , 2 0 1 8
Biomarker-Guided Versus Evidence-Based Treatment in Heart Failure J A N U A R Y 3 0 , 2 0 1 8 : 3 8 6 – 9 8
394recommended doses of beta-blockers (Scenario C),
estimated death or hospital admission occurred in
428 (95% CI: 391 to 466) patients. Up-titrating beta-
blockers to >50% of recommended dose compared
with #50% resulted in 24 fewer events (95% CI: 54
to 103; p ¼ 0.50). The biomarkers-based approach led
to 84 fewer events (95% CI: 40 to 128; p ¼ 0.01)
compared with the #50% recommended dose group.
This means that 1.3 (95% CI: 3.0 to 5.7) and 4.7 (95%
CI: 2.2 to 7.1) events could be prevented per 100
treated patients in both scenarios.
When considering up-titrating to both 50% of
recommended ACE inhibitor/ARB and beta-blocker
dose we estimated that 222 (95% CI: 147 to 298)
events could be prevented when all patients were
up-titrated to at least 50% recommended treatment
dose for both ACE inhibitors/ARBs and beta-
blockers. Another 14 (95% CI: 52 to 80) events
could be prevented when the decision to up-titrated
was based on a biomarker-based model (Online
Appendix).
For MRA treatment we estimated that not up-
titrating patients to $50% of recommended MRA
dose would result in 437 (95% CI: 405 to 469)
events. When we would up-titrate all patients, this
would be reduced with 222 (95% CI: 147 to 298;
p ¼ 0.0001) events to 215 (95% CI: 150 to 280). Our
biomarker-based model resulted in 236 (95% CI: 170
to 303; p ¼ 0.0004) less events than when no pa-
tient would be up-titrated to $50% of recommended
MRA dose.
CENTRAL ILLUSTRATION Biomarker-Guided Treatment in Heart Failure:



















Scenario A Scenario B Scenario C
Ouwerkerk, W. et al. J Am Coll Cardiol. 2018;71(4):386–98.
Estimated Kaplan-Meier survival curves with the expected event-free survival rate and time in months based on 3 scenarios (blue, orange,
and gray lines): scenario A, if all patients were up-titrated to $50% of recommended mineralocorticoid receptor antagonist (MRA) dose
(blue); scenario B, if all patients were up-titrated according to biomarker-selection model (orange); and scenario C, if no patient was
up-titrated to $50% of recommended of MRA dose (gray), with 95% conﬁdence interval (dashed lines).
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395DISCUSSION
We hypothesized that not every patient with heart
failure with reduced ejection fraction will beneﬁt
from maximal up-titration with either ACE inhibitors/
ARBs or beta-blockers. We therefore tested 3 hypo-
thetical scenarios: scenario A, in which all patients
were up-titrated to >50% of recommended ACE
inhibitor/ARB or beta-blocker dose; scenario B, in
which all patients were up-titrated or not based on
a biomarker model; and scenario C, in which no
patient was up-titrated to >50% of recommended
ACE inhibitor/ARB or beta-blocker dose (Central
Illustration). Our models estimated that the highest
number of events would have occurred in scenario C
and the lowest number of events in scenario B. Thepresent results from this novel approach suggest that
some patients do not beneﬁt from maximally recom-
mended doses.
There are many biomarkers known to inﬂuence
therapeutic response and survival (26,27), and there
have been many attempts to use biomarker levels for
evaluating treatment response and outcome (28).
However, no models were developed using a multi-
tude of biomarkers to estimate and compare the risk
of mortality or heart failure hospitalization in up-
titrated and non–up-titrated patients.
We recently published a meta-analysis on all
prognostic heart failure models and an average
C-statistics for predicting mortality or heart failure–
related hospitalization of 0.68 (29). Thus, the
biomarker-based treatment selection models in the
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396present paper have similar predictive performance
compared with existing models. Most of these prog-
nostic models were based on clinical and biographical
patient characteristics with few biomarkers. The as-
sociation of some biomarkers that we identiﬁed (e.g.,
NT-proBNP, BUN, ST2, hemoglobin) with mortality or
heart failure hospitalization risk in heart failure pa-
tients is well known (9,10,30–37), but a differential
predictive value in patients who were successfully
up-titrated versus those who were not is as yet un-
known. This observation may be useful to identify
residual heart failure disease and additional treat-
ment targets in heart failure patients. Although our
biomarker-based treatment selection models have
comparable performance to other prediction models,
the performance of these models is still modest and
they have large conﬁdence bounds. In this study, we
only looked at beneﬁt, and did not take harm into
account. Not up-titrating might be more beneﬁcial for
a patient; however, up-titrating might not do harm.
We decided to dichotomize up-titration into
successful or not successful. In clinical practice,
the actual doses of ACE inhibitors/ARBs and
beta-blockers vary substantially. As we recently
published data from BIOSTAT-CHF showing that
up-titrating patients to 50% to 99% of recommended
ACE inhibitor/ARB and beta-blocker doses results in
comparable survival or heart failure–related hospi-
talization reduction (21), we considered patients
successfully up-titrated when >50% of recommended
dose was achieved after 3 months of up-titration.
The BIOSTAT-CHF population mainly consists of
patients with advanced heart failure who may be
more likely to have limited beneﬁt from up-titration
of ACE inhibitor/ARB and beta-blocker therapy.
These patients may be worsened by even small doses
of beta-blockers, or they may experience excessive
hypotension and worsening renal function from ACE
inhibitors/ARBs. BIOSTAT-CHF was speciﬁcally
designed to record reasons for not up-titrating to
recommended treatment doses. Only in 26% and 22%
of the patients for ACE inhibitors/ARBs and beta-
blockers, this was caused by intolerance to the drug
because of organ dysfunction. In the majority of pa-
tients, no speciﬁc reason was provided (21). This
analysis supports the concept that even less clinically
ill patients may not be helped by ACE inhibitor/ARB
and beta-blocker up-titration.
There were signiﬁcant hemodynamic differences
(heart rate and blood pressure) between patients who
were up-titrated >50% of recommended treatment
dose and those who were not. This might suggest thatthese and other variables were at least partly
responsible for the different achieved up-titration
doses. We corrected for these difference by pro-
pensity score matching and inverse probability of
treatment weighing.
STUDY LIMITATIONS. Onemajor important limitation
of the present study is that heart failure treatment was
not randomly assigned in our study. Up-titration
of ACE inhibitors/ARBs and beta-blockers has
been shown to be beneﬁcial on average in many
randomized clinical trials and has been adopted into
the European Society of Cardiology heart failure
guidelines. It is striking, however, that in clinical
practice so many patients are not up-titrated to >50%
of recommended dose. We tried to adjust for
this treatment-indication bias, introduced in this
cohort-type BIOSTAT-CHF study, by 2 generally
accepted advanced statistical methods: propensity
scoring and inverse probability of treatment weighing.
Whether this corrected the treatment indication bias
sufﬁciently is unfortunately not testable.
A second limitation is the large number of bio-
markers that we analyzed, which increased the
chance of false positive ﬁndings. We used Bonferroni
correction of p values and we used sparse regression
models to minimize the risk of overﬁtting. Lasso
penalization is known to yield too large regression
models (with too many predictor variables) (38), so
our models might still be somewhat larger than
necessary (on average >23 biomarkers). We used a
repeated split-sample technique to cross-validate
beneﬁt and ﬁt statistics to reduce the effect of
overﬁtting.
A third limitation of our analyses was that we
ignored patients who died in the ﬁrst 3 months of the
up-titration period. We excluded 151 deaths and the
survival at 3 months was only 93%. We made a pre-
dictionmodel for the risk of death within 3months and
found that ﬁbroblast growth factor 23, NT-proBNP,
BNP, low hemoglobin, troponin I, ET1, ST2, WAP-4C,
and C-reactive protein were the most important pre-
dictors of death within 3 months. This selection of
biomarkers coincided largely with the set of bio-
markers that we identiﬁed as prognostic in the patients
who were not successfully up-titrated for both ACE
inhibitors/ARBs and beta-blockers. Therefore, we as-
sume that the presented resultswere not largely biased
by the removal of the 151 deaths. We only had MRA
dose data available after 9 months follow-up. This in-
troduces additional bias because excluded even
more patients than for the ACE inhibitor/ARB and
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Not all patients with heart failure beneﬁt from up-
titrating treatment doses of recommended neurohormonal in-
hibitor medication. Predicting beneﬁt based on individual
biomarker proﬁles results in greater reduction of mortality
and/or heart–failure-related hospitalization, although the dif-
ference is small.
TRANSLATIONAL OUTLOOK: Randomized trials comparing
various models for selection of biomarker-guided treatment may
provide insight into the pathogenesis of heart failure and expand
treatment options
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397beta-blocker analyses. We tried to correct for this by
inverse probability weighting. Although we cannot
test if this was sufﬁcient, we think the MRA data add
important information to our models.
Because not all biomarkers used in our treatment
selection models were measured in the validation
cohort of the BIOSTAT-CHF study of 1,728 patients, we
unfortunately could not validate our results in this
cohort. In the future, and when funding is available we
aim to measure the missing biomarkers and validate
our treatment selection models in this cohort as well.
We found substantial differences between patients
of which the model assumed not to beneﬁt from
ACE inhibitor/ARB up-titration and patients of
which the model assumed not to beneﬁt from beta-
blocker up-titration. Patients not beneﬁtting from
ACE inhibitor/ARB up-titration were younger, with
lower BNP and NT-proBNP, and higher hemoglobin
levels. Patients not beneﬁtting from beta-blocker
up-titration, conversely, were more often older, had
higher BNP and NT-proBNP, and had lower hemoglo-
bin compared with patients beneﬁtting from beta-
blocker up-titration. BUN was elevated and heart
rate was lower in both patients not beneﬁtting
from ACE inhibitor/ARB up-titration and patients not
beneﬁtting from beta-blocker up-titration.
Other possible limitations that could not be
addressed in our cohort are the fact that our data are
unfortunately limited to Caucasian patients only, and
that there was a very low use of device therapy. This
would possibly limit the use of our biomarker selec-
tion model in a more heterogeneous population. The
percentage of device therapy is nevertheless compa-
rable to the EMPHASIS-HF (Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart
Failure) study, which recruited patients at the same
time as BIOSTAT-CHF (39).
Biomarkers predictive for mortality or hospitaliza-
tion were also markedly different between patients
who were successfully up-titrated or not. This might
have been expected because biomarkers related to
ACE inhibition or ARB and beta-blocking pathways
are likely to change substantially as a result of up-
titration (40).CONCLUSIONS
A biomarker-based treatment up-titration choice in
patients with heart failure was favorable over both a
hypothetical scenario in which all patients would
have been successfully up-titrated to >50% of rec-
ommended of ACE inhibitor/ARB and beta-blocker
dose and $50% MRA dose. We estimated that 1 in
50, 1 in 3, and 1 in 8 patients would not beneﬁt from
up-titration with ACE inhibitor/ARB, beta-blocker, or
MRA, but their mortality or hospitalization hazards
do not increase much by up-titration. Because of the
nature of this study, and the small differences be-
tween biomarker-based treatment choice and the
scenario in which all patients would have been suc-
cessfully up-titrated, we suggest that up-titration
should always be attempted in heart failure pa-
tients, which should lead to improved treatment of
life-saving therapies across Europe.
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